Trial Outcomes & Findings for VANISH for Chronic Low Back Pain (NCT NCT04236804)

NCT ID: NCT04236804

Last Updated: 2025-04-11

Results Overview

Daily dose of oral opioids recorded as morphine equivalents will be collected

• Recruitment status: COMPLETED
• Study phase: NA
• Target enrollment: 20 participants
• Primary outcome timeframe: Week 0
• Results posted on: 2025-04-11

Participant Flow

Participant milestones

Measure	TMC-CP01 Intervention Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Overall Study STARTED	10	10
Overall Study COMPLETED	10	10
Overall Study NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

VANISH for Chronic Low Back Pain

Baseline characteristics by cohort

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.	Total n=20 Participants Total of all reporting groups
Age, Continuous	55.70 Years STANDARD_DEVIATION 14.30 • n=5 Participants	58.8 Years STANDARD_DEVIATION 10.11 • n=7 Participants	57.25 Years STANDARD_DEVIATION 12.16 • n=5 Participants
Sex: Female, Male Female	4 Participants n=5 Participants	8 Participants n=7 Participants	12 Participants n=5 Participants
Sex: Female, Male Male	6 Participants n=5 Participants	2 Participants n=7 Participants	8 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants
Race (NIH/OMB) White	9 Participants n=5 Participants	9 Participants n=7 Participants	18 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Region of Enrollment United States	10 participants n=5 Participants	10 participants n=7 Participants	20 participants n=5 Participants

PRIMARY outcome

Timeframe: Week 0

Daily dose of oral opioids recorded as morphine equivalents will be collected

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Opioid Use Via Subject Report	47.5 morphine milligram equivalent Standard Deviation 36.53	21.75 morphine milligram equivalent Standard Deviation 23.19

SECONDARY outcome

Timeframe: Week 4

The amount and dosing of opioid medications taken by each subject will be recorded throughout the study. The lower the average daily morphine milligram equivalent [MME], the better the outcomes. Outcomes will be measured over the span of the study and compared between the two groups.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Opioid Use Via Subject Report	47.27 MME Standard Deviation 36.77	10.75 MME Standard Deviation 7.34

SECONDARY outcome

Timeframe: Week 8

The amount and dosing of opioid medications taken by each subject will be recorded throughout the study. The lower the average daily morphine milligram equivalent [MME], the better the outcomes. Outcomes will be measured over the span of the study and compared between the two groups.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Opioid Use Via Subject Report	47.27 MME Standard Deviation 36.77	10.62 MME Standard Deviation 7.36

SECONDARY outcome

Timeframe: 8 Weeks

Population: HRV data were not collected due to a malfunction in the Flowly app, which was in beta testing during the study. The app was intended to collect HRV via a paired biometric sensor, but it failed to reliably communicate with the device. As a result, HRV measurements were not transmitted or stored, and no usable data were available for analysis.

HRV will be modulated by conforming respiration and heart rate to optimal breathing patterns. The games are designed to guide subjects' physiology to a more optimal state for pain reduction using biofeedback. Resonant breathing is breathing that activates the coordinated function of oscillating body systems. This breathing increases your Heart Rate Variability. Greater Heart Rate Variability (a higher HRV score) at rest indicates better outcomes. Outcomes will be measured over the span of the study and compared between the two groups.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: weekly, up to 8 weeks

The Craving Index questionnaire on the Flowly app assesses opioid cravings using 6 qualitatively scaled questions, ranging from 'none' (minimum score: 0) to 'the greatest possibility' (maximum score: 5 per question, total score: 30). Lower scores indicate less frequent opioid cravings, suggesting better outcomes. Measurements were assessed weekly, and the analysis focused on comparing scores between baseline and 8 weeks to evaluate changes in cravings between the two groups.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Opioid Cravings Using the Craving Index at 8 Weeks	0.60 score on a scale Standard Deviation 7.56	0.83 score on a scale Standard Deviation 4.92

SECONDARY outcome

Timeframe: Assessed weekly, change from baseline and Week 8 reported

The investigators used the PROMIS Physical Function Short Form T-score to assess key patient-centered outcomes related to physical function. This assessment includes 4 physical function-related questions, each scored on a 5-point Likert scale (1 = unable to do, 5 = without any difficulty). The raw total score ranges from a minimum of 4 to a maximum of 20.

Responses were converted to T-scores, where the mean in the general population is 50 with a standard deviation of 10. Higher T-scores indicate better physical function, while lower T-scores suggest worse physical function. Clinically relevant thresholds may indicate that lower scores are associated with greater physical disability.

Measurements were conducted at baseline and Week 8, with the analysis focused on comparing changes in physical function between the two groups.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Physical Function Using PROMIS Physical Function Short Form T-score at 8 Weeks	0.07 T-score Standard Deviation 2.89	-1.41 T-score Standard Deviation 4.24

SECONDARY outcome

Timeframe: Baseline and Week 8

The investigators used the PROMIS Fatigue Short Form T-score to assess key patient-centered outcomes related to fatigue. This assessment includes 4 fatigue-related questions, each scored on a 5-point Likert scale (1 = not at all, 5 = very much). The raw total score ranges from a minimum of 4 to a maximum of 20.

Responses were converted to T-scores, where the mean in the general population is 50 with a standard deviation of 10. Higher T-scores indicate greater fatigue, while lower T-scores suggest less fatigue, which reflects better outcomes. Clinically relevant thresholds suggest that elevated T-scores may indicate increased fatigue severity.

Measurements were conducted at baseline and Week 8, with the analysis focused on comparing changes in fatigue levels between the two groups.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Fatigue Using PROMIS Fatigue Short Form T-score at 8 Weeks	0.17 T-score Standard Deviation 5.05	0.61 T-score Standard Deviation 8.09

SECONDARY outcome

Timeframe: Assessed weekly, change from baseline and Week 8 reported

The investigators used the PROMIS Pain Interference Short Form to assess how pain impacts daily activities. This measure includes 5 pain-related questions, each scored on a 5-point Likert scale (1 = not at all, 5 = very much). The raw total score (range: 5 to 25) was converted to a standardized T-score (mean = 50, SD = 10).

Higher T-scores indicate greater pain interference, while lower T-scores suggest less interference (better outcomes). A T-score of 60+ may indicate clinically significant pain interference, while 40 or lower suggests minimal interference.

Measurements were conducted over the study, with scores compared between baseline and 8 weeks to assess changes in pain interference.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Pain Interference Using the PROMIS Pain Interference Short Form at 8 Weeks	-1.47 T-score Standard Deviation 3.69	-1.75 T-score Standard Deviation 3.22

SECONDARY outcome

Timeframe: Assessed weekly, change from baseline and Week 8 reported

The investigators used the PROMIS Pain Intensity Item to assess patients' self-reported pain levels. This measure consists of one question, scored on an 11-point Likert scale (0 = no pain, 10 = worst imaginable pain). The raw score was converted to a standardized T-score (mean = 50, SD = 10).

Higher T-scores indicate greater pain intensity, while lower T-scores suggest less pain (better outcomes). A T-score of 60+ may indicate clinically significant pain, while 40 or lower suggests mild or minimal pain.

Measurements were conducted throughout the study, with scores compared between baseline and 8 weeks to assess changes in pain intensity.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Pain Intensity Using the PROMIS Pain Intensity Item at 8 Weeks	0.2 T-score Standard Deviation 1.32	0.14 T-score Standard Deviation 1.07

SECONDARY outcome

Timeframe: Assessed weekly, change from baseline and Week 8 reported

The investigators used the PROMIS Sleep Disturbance Short Form to assess patient-reported sleep difficulties. This measure includes 4 items, each rated on a 5-point Likert scale (1 = not at all, 5 = very much). The raw score (range: 4 to 20) was converted to a T-score (mean = 50, SD = 10).

Higher T-scores indicate greater sleep disturbance (worse outcomes), while lower T-scores suggest better sleep quality. A T-score of 60+ may indicate clinically significant sleep disturbance, while 40 or lower suggests minimal issues.

Measurements were conducted throughout the study, with scores compared between baseline and 8 weeks to assess changes in sleep disturbance.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Sleep Disturbance Using the PROMIS Sleep Disturbance Short Form at 8 Weeks	-1.82 T-score Standard Deviation 5.73	-0.47 T-score Standard Deviation 4.51

SECONDARY outcome

Timeframe: Assessed weekly, change from baseline and Week 8 reported

The investigators used the PROMIS Ability to Participate in Social Roles and Activities Short Form to assess social participation. This measure includes 4 items, each rated on a 5-point Likert scale (1 = never, 5 = always). The raw score (range: 4 to 20) was converted to a T-score (mean = 50, SD = 10).

Higher T-scores indicate greater ability to engage in social roles and activities (better outcomes), while lower scores suggest more social restrictions. A T-score below 40 may indicate clinically significant limitations in social participation.

Measurements were conducted throughout the study, with scores compared between baseline and 8 weeks to assess changes in social participation.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Ability to Participate in Social Roles and Activities Using the PROMIS Short Form at 8 Weeks	1.95 T-score Standard Deviation 5	0.04 T-score Standard Deviation 4.23

SECONDARY outcome

Timeframe: Assessed weekly, change from baseline and Week 8 reported

The investigators used the PROMIS Depression Short Form to assess depressive symptoms. This measure includes 4 items, each rated on a 5-point Likert scale (1 = never, 5 = always). The raw score (range: 4 to 20) was converted to a T-score (mean = 50, SD = 10).

Higher T-scores indicate greater levels of depression (worse outcomes), while lower scores reflect fewer depressive symptoms. A T-score above 60 suggests clinically significant depression, while a T-score below 50 reflects better mental health relative to the general population.

Measurements were conducted throughout the study, with scores compared between baseline and 8 weeks to assess changes in depressive symptoms.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Depression Using the PROMIS Short Form at 8 Weeks	-1.08 T-score Standard Deviation 4.21	-3.22 T-score Standard Deviation 6.35

SECONDARY outcome

Timeframe: Assessed weekly, change from baseline and Week 8 reported

The investigators used the PROMIS Anxiety Short Form to assess anxiety symptoms. This measure includes 4 items, each rated on a 5-point Likert scale (1 = never, 5 = always). The raw score (range: 4 to 20) was converted to a T-score (mean = 50, SD = 10).

Higher T-scores indicate greater levels of anxiety (worse outcomes), while lower scores reflect reduced anxiety symptoms. A T-score above 60 suggests clinically significant anxiety, while a T-score below 50 reflects better emotional health relative to the general population.

Measurements were conducted throughout the study, with scores compared between baseline and 8 weeks to assess changes in anxiety symptoms.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Anxiety Using the PROMIS Short Form at 8 Weeks	-4.05 T-score Standard Deviation 7.79	-2.62 T-score Standard Deviation 5.59

SECONDARY outcome

Timeframe: Assessed weekly, change from baseline and Week 8 reported

The investigators used the PROMIS Emotional Support Short Form to assess patient-centered outcomes related to loneliness. This measure includes 4 items, each rated on a 5-point Likert scale (1 = never, 5 = always). The raw score (range: 4 to 20) was converted to a T-score (mean = 50, SD = 10).

Higher T-scores indicate greater loneliness (worse outcomes), while lower scores suggest better emotional support. A T-score above 60 suggests clinically significant loneliness, while a T-score below 50 reflects better perceived emotional support relative to the general population.

Measurements were conducted throughout the study, with scores compared between baseline and 8 weeks to assess changes in loneliness.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change From Baseline in Loneliness Using the PROMIS Emotional Support Short Form at 8 Weeks	-2 T-score Standard Deviation 4.08	-4 T-score Standard Deviation 5.66

SECONDARY outcome

Timeframe: Week 0

The investigators will use the PainDetect Questionnaire, a validated tool to assess patients' perceptions and feelings about pain. The questionnaire includes 15 multiple-choice questions and a drawing of localized pain, yielding a total score that ranges from 0 (minimum) to 38 (maximum). Lower scores indicate less neuropathic pain and suggest better outcomes.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Feelings About Pain	16.9 score on a scale Standard Deviation 9.57	16.8 score on a scale Standard Deviation 10.73

SECONDARY outcome

Timeframe: Week 4

The investigators will use the PainDetect Questionnaire, a validated tool to assess patients' perceptions and feelings about pain. The questionnaire includes 15 multiple-choice questions and a drawing of localized pain, yielding a total score that ranges from 0 (minimum) to 38 (maximum). Lower scores indicate less neuropathic pain and suggest better outcomes.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Feelings About Pain	16.89 score on a scale Standard Deviation 7.06	17 score on a scale Standard Deviation 5.29

SECONDARY outcome

Timeframe: Week 8

The investigators will use the PainDetect Questionnaire, a validated tool to assess patients' perceptions and feelings about pain. The questionnaire includes 15 multiple-choice questions and a drawing of localized pain, yielding a total score that ranges from 0 (minimum) to 38 (maximum). Lower scores indicate less neuropathic pain and suggest better outcomes.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Feelings About Pain	14.9 score on a scale Standard Deviation 8.16	16.5 score on a scale Standard Deviation 8.04

SECONDARY outcome

Timeframe: Week 0

The investigators will measure subjects' salivary cortisol levels using validated laboratory techniques. Cortisol levels are reported in micrograms per deciliter (mcg/dL) and have no predefined minimum or maximum values. Lower cortisol levels indicate better outcomes.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Salivary Cortisol Levels	3.68 mcg/dL Standard Deviation 2.32	5.07 mcg/dL Standard Deviation 5.06

SECONDARY outcome

Timeframe: Week 4

Population: Data were not collected at Week 4 because salivary cortisol levels were only measured at baseline (Week 0) and the study endpoint (Week 8). No data exist for this time point.

The investigators will measure subjects' salivary cortisol levels using validated laboratory techniques. Cortisol levels are reported in micrograms per deciliter (mcg/dL) and have no predefined minimum or maximum values. Lower cortisol levels indicate better outcomes.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 8

The investigators will measure subjects' salivary cortisol levels using validated laboratory techniques. Cortisol levels are reported in micrograms per deciliter (mcg/dL) and have no predefined minimum or maximum values. Lower cortisol levels indicate better outcomes.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Salivary Cortisol Levels	6.72 mcg/dL Standard Deviation 5.73	8.38 mcg/dL Standard Deviation 9.15

SECONDARY outcome

Timeframe: Week 0

Population: Urine drug screen data were not collected due to two key barriers: (1) the clinical personnel required to administer the tests were not consistently available during study visits, and (2) the cost of performing quantitative urine drug screens for each participant was beyond the scope of the study's budget. As a result, no data are available for this outcome.

The amount of opiates found in the urine of each subject will be recorded throughout the study. The lower the detected morphine milligram equivalent [MME], the better the outcomes. Outcomes will be measured over the span of the study and compared between the two groups.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 4

Population: Urine drug screen data were not collected due to two key barriers: (1) the clinical personnel required to administer the tests were not consistently available during study visits, and (2) the cost of performing quantitative urine drug screens for each participant was beyond the scope of the study's budget. As a result, no data are available for this outcome.

The amount of opiates found in the urine of each subject will be recorded throughout the study. The lower the detected morphine milligram equivalent [MME], the better the outcomes. Outcomes will be measured over the span of the study and compared between the two groups.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 8

Population: Urine drug screen data were not collected due to two key barriers: (1) the clinical personnel required to administer the tests were not consistently available during study visits, and (2) the cost of performing quantitative urine drug screens for each participant was beyond the scope of the study's budget. As a result, no data are available for this outcome.

The amount of opiates found in the urine of each subject will be recorded throughout the study. The lower the detected morphine milligram equivalent [MME], the better the outcomes. Outcomes will be measured over the span of the study and compared between the two groups.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 0

The Subjective Opiate Withdrawal Scale (SOWS) will assess subjects' withdrawal symptoms using 16 multiple-choice questions, each scored from 0 (not at all) to 4 (extremely). The total score ranges from a minimum of 0 to a maximum of 64. Lower scores indicate better outcomes and fewer withdrawal symptoms.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Withdrawal Symptoms Using Opiate Withdrawal Scale	8 score on a scale Standard Deviation 5.37	3.7 score on a scale Standard Deviation 2.83

SECONDARY outcome

Timeframe: Week 4

The Subjective Opiate Withdrawal Scale (SOWS) will assess subjects' withdrawal symptoms using 16 multiple-choice questions, each scored from 0 (not at all) to 4 (extremely). The total score ranges from a minimum of 0 to a maximum of 64. Lower scores indicate better outcomes and fewer withdrawal symptoms.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Withdrawal Symptoms Using Opiate Withdrawal Scale	7.67 score on a scale Standard Deviation 4.82	14 score on a scale Standard Deviation 18.52

SECONDARY outcome

Timeframe: Week 8

The Subjective Opiate Withdrawal Scale (SOWS) will assess subjects' withdrawal symptoms using 16 multiple-choice questions, each scored from 0 (not at all) to 4 (extremely). The total score ranges from a minimum of 0 to a maximum of 64. Lower scores indicate better outcomes and fewer withdrawal symptoms.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Withdrawal Symptoms Using Opiate Withdrawal Scale	7.6 score on a scale Standard Deviation 6.35	5.67 score on a scale Standard Deviation 6.92

SECONDARY outcome

Timeframe: Week 0

The Pain Catastrophizing Scale (PCS) will assess subjects' beliefs about pain using 13 multiple-choice questions, each scored from 1 (not at all) to 5 (all the time). The total score ranges from a minimum of 13 to a maximum of 65. Lower scores indicate better outcomes and less catastrophizing about pain.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Beliefs About Pain Using Pain Catastrophizing Scale	31.33 score on a scale Standard Deviation 9.12	25.8 score on a scale Standard Deviation 10.9

SECONDARY outcome

Timeframe: Week 4

The Pain Catastrophizing Scale (PCS) will assess subjects' beliefs about pain using 13 multiple-choice questions, each scored from 1 (not at all) to 5 (all the time). The total score ranges from a minimum of 13 to a maximum of 65. Lower scores indicate better outcomes and less catastrophizing about pain.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Beliefs About Pain Using Pain Catastrophizing Scale	34.4 score on a scale Standard Deviation 10.01	25.29 score on a scale Standard Deviation 7.54

SECONDARY outcome

Timeframe: Week 8

The Pain Catastrophizing Scale (PCS) will assess subjects' beliefs about pain using 13 multiple-choice questions, each scored from 1 (not at all) to 5 (all the time). The total score ranges from a minimum of 13 to a maximum of 65. Lower scores indicate better outcomes and less catastrophizing about pain.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Beliefs About Pain Using Pain Catastrophizing Scale	27.1 score on a scale Standard Deviation 9.48	23.71 score on a scale Standard Deviation 7.83

SECONDARY outcome

Timeframe: Week 0

The Treatment Expectancy Short Form assesses subjects' expectations and confidence in their treatment using 6 items, each scored on a 5-point Likert scale (1 = not at all, 5 = very much). The raw score (range: 6 to 30) is converted to a T-score (mean = 50, SD = 10) for standardized interpretation.

Higher T-scores indicate greater treatment expectancy, suggesting more positive beliefs about treatment efficacy. Lower T-scores reflect greater skepticism or uncertainty. A T-score above 60 may indicate high confidence in treatment, while a T-score below 40 suggests low expectancy.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Treatment Expectancy Using the Treatment Expectancy Short Form at Week 0	50.19 t-score Standard Deviation 6.03	51.33 t-score Standard Deviation 5.7

SECONDARY outcome

Timeframe: Week 4

The Treatment Expectancy Short Form assesses subjects' expectations and confidence in their treatment using 6 items, each scored on a 5-point Likert scale (1 = not at all, 5 = very much). The raw score (range: 6 to 30) is converted to a T-score (mean = 50, SD = 10) for standardized interpretation.

Higher T-scores indicate greater treatment expectancy, suggesting more positive beliefs about treatment efficacy. Lower T-scores reflect greater skepticism or uncertainty. A T-score above 60 may indicate high confidence in treatment, while a T-score below 40 suggests low expectancy.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Treatment Expectancy Using the Treatment Expectancy Short Form at Week 4	46.04 t-score Standard Deviation 6.95	51.43 t-score Standard Deviation 5.45

SECONDARY outcome

Timeframe: Week 8

The Treatment Expectancy Short Form evaluates subjects' expectations and confidence in their treatment using 6 items, each rated on a 5-point Likert scale (1 = not at all, 5 = very much). The raw score (range: 6 to 30) is converted to a T-score (mean = 50, SD = 10) for standardized interpretation.

Higher T-scores indicate greater treatment expectancy, suggesting more positive beliefs about treatment efficacy. Lower T-scores reflect greater skepticism or uncertainty. A T-score above 60 may indicate high confidence in treatment, while a T-score below 40 suggests low expectancy.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Treatment Expectancy Using the Treatment Expectancy Short Form at Week 8	50.48 T-score Standard Deviation 8.65	43.98 T-score Standard Deviation 10.21

SECONDARY outcome

Timeframe: Week 0

The Positive Outlook Short Form measures subjects' perceptions and feelings about the future using 6 items, each rated on a 5-point Likert scale (1 = not at all, 5 = very much). The raw score (range: 6 to 30) is converted to a T-score (mean = 50, SD = 10) for standardized interpretation.

Higher T-scores indicate greater optimism and a more positive outlook, suggesting better psychological well-being. Lower T-scores reflect greater pessimism or concerns about the future. A T-score above 60 may indicate high optimism, while a T-score below 40 suggests low optimism or increased negative expectations.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Positive Outlook Using the Positive Outlook Short Form at Week 0	46.06 T-score Standard Deviation 9.53	50.22 T-score Standard Deviation 11.77

SECONDARY outcome

Timeframe: Week 4

The Positive Outlook Short Form measures subjects' perceptions and feelings about the future using 6 items, each rated on a 5-point Likert scale (1 = not at all, 5 = very much). The raw score (range: 6 to 30) is converted to a T-score (mean = 50, SD = 10) for standardized interpretation.

Higher T-scores indicate greater optimism and a more positive outlook, suggesting better psychological well-being. Lower T-scores reflect greater pessimism or concerns about the future. A T-score above 60 may indicate high optimism, while a T-score below 40 suggests low optimism or increased negative expectations.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Positive Outlook Using the Positive Outlook Short Form at Week 4	46.77 T-score Standard Deviation 6.47	53.43 T-score Standard Deviation 17.6

SECONDARY outcome

Timeframe: Week 8

The Positive Outlook Short Form evaluates subjects' perceptions and expectations about the future using 6 items, each rated on a 5-point Likert scale (1 = not at all, 5 = very much). The raw score (range: 6 to 30) is converted to a T-score (mean = 50, SD = 10) for standardized interpretation.

Higher T-scores indicate greater optimism and a more positive outlook, suggesting better psychological well-being. Lower T-scores reflect greater pessimism or concerns about the future. A T-score above 60 may indicate high optimism, while a T-score below 40 suggests low optimism or increased negative expectations.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Positive Outlook Using the Positive Outlook Short Form at Week 8	46.86 T-score Standard Deviation 8.89	50.48 T-score Standard Deviation 12.21

SECONDARY outcome

Timeframe: Week 0

The Current Opioid Misuse Measure (COMM) questionnaire assesses recent behaviors using 17 multiple-choice questions, with scores ranging from a minimum of 0 to a maximum of 68. Lower scores suggest better outcomes and less likelihood of opioid misuse.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Recent Behaviors Using the Current Opioid Misuse Measure (COMM)	11 score on a scale Standard Deviation 6.07	9 score on a scale Standard Deviation 5.93

SECONDARY outcome

Timeframe: Week 4

The Current Opioid Misuse Measure (COMM) questionnaire assesses recent behaviors using 17 multiple-choice questions, with scores ranging from a minimum of 0 to a maximum of 68. Lower scores suggest better outcomes and less likelihood of opioid misuse.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Recent Behaviors Using the Current Opioid Misuse Measure (COMM)	7.89 score on a scale Standard Deviation 5.78	6 score on a scale Standard Deviation 2

SECONDARY outcome

Timeframe: Week 8

The Current Opioid Misuse Measure (COMM) questionnaire assesses recent behaviors using 17 multiple-choice questions, with scores ranging from a minimum of 0 to a maximum of 68. Lower scores suggest better outcomes and less likelihood of opioid misuse.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Recent Behaviors Using the Current Opioid Misuse Measure (COMM)	10.10 score on a scale Standard Deviation 7.36	3.17 score on a scale Standard Deviation 2.93

SECONDARY outcome

Timeframe: Week 0

The Tellegen Absorption Scale (TAS) assesses an individual's ability to become deeply engaged in a task or an aspect of their environment. The scale consists of 34 true-or-false items, where each "true" response is scored as 1, and each "false" response is scored as 0.

The total score ranges from 0 to 34, with higher scores indicating a greater capacity for absorption and immersive engagement. This measure evaluates attentional focus and deep engagement in activities, which may be relevant for assessing response to virtual reality interventions.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Task Absorption Using the Tellegen Absorption Scale (TAS) at Week 0	10.2 Units on a scale Standard Deviation 7.41	14.3 Units on a scale Standard Deviation 8.53

SECONDARY outcome

Timeframe: Week 4

The Tellegen Absorption Scale (TAS) assesses an individual's ability to become deeply engaged in a task or an aspect of their environment. The scale consists of 34 true-or-false items, where each "true" response is scored as 1, and each "false" response is scored as 0.

The total score ranges from 0 to 34, with higher scores indicating a greater capacity for absorption and immersive engagement. This measure evaluates attentional focus and deep engagement in activities, which may be relevant for assessing response to virtual reality interventions.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Task Absorption Using the Tellegen Absorption Scale (TAS) at Week 4	9.22 Units on a scale Standard Deviation 8.15	17.67 Units on a scale Standard Deviation 8.02

SECONDARY outcome

Timeframe: Week 8

The Tellegen Absorption Scale (TAS) assesses an individual's ability to become deeply engaged in a task or an aspect of their environment. The scale consists of 34 true-or-false items, where each "true" response is scored as 1, and each "false" response is scored as 0.

The total score ranges from 0 to 34, with higher scores indicating a greater capacity for absorption and immersive engagement. This measure evaluates attentional focus and deep engagement in activities, which may be relevant for assessing response to virtual reality interventions.

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Assessment of Task Absorption Using the Tellegen Absorption Scale (TAS) at Week 8	8.4 Units on a scale Standard Deviation 7.15	16 Units on a scale Standard Deviation 7.92

SECONDARY outcome

Timeframe: Baseline and Week 8 (Week 8 value is the average of daily scores from that week)

Subjects rated their current pain level using the 0-10 Visual Analog Scale (VAS) within the Flowly app, where 0 represents no pain and 10 represents the worst imaginable pain. Pain scores were recorded immediately before and after each VR session, which took place daily throughout the study.

For analysis, pain scores were assessed at baseline and at Week 8. The Week 8 value represents the average of daily post-session scores recorded during the final week of the study. The change in pain levels was calculated by comparing the baseline value to the Week 8 average.

Higher scores indicate greater pain intensity, while lower scores suggest better outcomes (i.e., pain reduction).

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change in Pain Level Before vs After Intervention Via Flowly App	0.2 Units on a scale Standard Deviation 1.32	0.14 Units on a scale Standard Deviation 1.07

SECONDARY outcome

Timeframe: Baseline and Week 8 (Week 8 value is the average of daily scores from that week)

Subjects rated their current anxiety level using the 0-10 Visual Analog Scale (VAS) within the Flowly app, where 0 represents no anxiety and 10 represents the worst imaginable anxiety. Anxiety scores were recorded immediately before and after each VR session, which took place daily throughout the study.

For analysis, anxiety scores were assessed at baseline and at Week 8. The Week 8 value represents the average of daily post-session scores recorded during the final week of the study. The change in anxiety levels was calculated by comparing the baseline value to the Week 8 average.

Higher scores indicate greater anxiety levels, while lower scores suggest better outcomes (i.e., anxiety reduction).

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change in Anxiety Level From Baseline to 8 Weeks Via Flowly App	-4.05 Units on a scale Standard Deviation 7.79	-2.62 Units on a scale Standard Deviation 5.59

SECONDARY outcome

Timeframe: Baseline and Week 8 (Week 8 value is the average of daily scores from that week)

Subjects rated their current depression level using the 0-10 Visual Analog Scale (VAS) within the Flowly app, where 0 represents no depression and 10 represents the worst imaginable depression. Depression scores were recorded immediately before and after each VR session, which took place daily throughout the study.

For analysis, depression scores were assessed at baseline and at Week 8. The Week 8 value represents the average of daily post-session scores recorded during the final week of the study. The change in depression levels was calculated by comparing the baseline value to the Week 8 average.

Higher scores indicate greater depression levels, while lower scores suggest better outcomes (i.e., depression reduction).

Outcome measures

Measure	TMC-CP01 Intervention n=10 Participants Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines. Flowly (TMC-CP01): TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.	Standard of Care n=10 Participants Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
Change in Depression Level From Baseline to 8 Weeks Via Flowly App	-1.08 Units on a scale Standard Deviation 4.21	-3.22 Units on a scale Standard Deviation 6.35

Adverse Events

TMC-CP01 Intervention

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Standard of Care

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Brian O'Connell

University of Pittsburgh

Phone: 3023997506

Email: oconnellb2@upmc.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place